SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
FDA Calendar Updates: MELA, PGNX, VPHM, WYE
WYE
|
|
|
+3.78%
in
97 days
<> Below is a summary of updates to the <font> BioMedReports.com FDA Calendar </font> , which includes a database of 288 entries as of 8/5/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage cli...
|
New Preventive Medicine Index
WYE
|
|
|
+3.59%
in
192 days
(closed on 08/05/09)
One of the major reasons behind Pfizer's (PFE) interest in acquiring Wyeth (WYE) is the latter's focus on products outside of traditional pharmaceuticals – with 60% of Wyeth's revenue from last year derived from biological therapeutics and vaccines. It remains to be seen what happens to Wyeth's proposed deal to acquire Dutch vaccine maker Crucell (CRXL); however since it is much smaller (around $1B) and focuses on the development of vaccines, Pfizer would likely be interested in both companies together. <> With the focus on preven...
|
Trading the Trials and FDA Decision Calendar
WYE
|
|
|
+0.00%
in
14 hours
(closed on 01/25/09)
Trading the Trials and FDA Decision Calendar The tables at my website links below feature an updated calendar of 80 expected FDA new product decisions and 89 pending clinical trial result estimates + pending FDA re-submissions. Click here for a link to my previous FDA calendars and click here for a list of 14 extreme trades of companies with market caps below $100M and pending new drug decisions at the FDA. <> Below is a summary of the major updates on the calendar...
|
Pharma looks like good value
WYE
|
|
|
+3.45%
in
670 days
In my opinion, global large-cap pharmacueticial stocks, including Pfizer , Novartis , Astrazenca , GlaxoSmithKline , Wyeth and Eli Lilly are currently substantially undervalued. These companies are currently paying out huge dividends and trading at sensible P/Es. Unlike their small-cap high-risk research counterparts, these blue-chip stocks represent strong, yet low risk growth. Why risk your money on an obscure new cure for bird-flu, from a dodgy one-man company, when you don't have to?
While sales of their products may be slowing in the OECD developed worl...
|
From the Blogosphere
Big Pharma and Biotech – Industry Outlook
|
|
|
The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.
According to IMS Health (RX), this is the main reason why global pharmaceutical market growth will be restricted to the mid-single digits through 2013. Over the next five years, products that currently generate about $137 billion in sales are expected to face generic co...
|
Bionovo: Challenges Ahead, But Poised to Move Higher
The Women’s Health Initiative ('WHI'), a study that demonstrated several lethal side-effects of hormone replacement therapy ('HRT'), has left many pharmaceutical companies scrambling to advance alternative therapies to meet the unique market demand created by the drop in hormone sales. Although several therapies have advanced to late-stage clinical studies, few represent a truly novel approach. <>Pristiq, Wyeth’s (WYE) new treatment for depression and potentially –post menopausal hot flashes, is merely a metabolite of the multi-billion dollar blockbuster, Effexor. Aprella, Wyeth’s in<><><>...
|
Options Update: Pfizer volatility low into EPS and pending merger with Wyeth
Filed under: Pfizer (PFE)  Pfizer (NYSE: PFE) closed at $17.10. PFE is expected to report Q3 EPS on October 20. Pfizer is expected to close on the acquisition of Wyeth (NYSE: WYE) for $33 in cash and 0.985 of a share of Pfizer by the end of 2009. PFE call option volume of 32,111 contracts compares to put volume of 2,590 contracts PFE October and November option implied volatility of 30 is below its 26-week average of 33, according to Track Data, suggesting decreasing price movement.
<>Financial Select Sector (NYSE: XLF) overall volatility at 39; below a level of 129 from November 2008 and above ...
|
First Solar to join the S&P 500 Index
Filed under: Pfizer (PFE), Indices, S and P 500  Late Thursday, Standard & Poor's announced a few changes to its U.S. indices. The reason for the changes are that Wyeth (NYSE: WYE) is being acquired by Pfizer (NYSE: PFE), leaving an opening in both the S&P 100 and S&P 500 (SPX). I want to focus on the stock that will replace WYE in the SPX, First Solar (NASDAQ: FSLR). In after-hours trading, FSLR jumped more than 6% in response to the announcement.
FSLR manufactures solar modules and is a major benefactor of what I like to call the "green rush" that took place during the past two years. FSLR c...
|
Stock Watch: CSUH.OB, MHTX.OB, BIEL.PK, SPHRY.PK
TRBN: [correction]
In response to my recent post regarding Trubion Pharmaceuticals, I received an email from Amy, who works for the company, pointing out the fact that I mis-identified one of their Wyeth (WYE)-partnered drugs, TRU-015 as TRU-105. I've corrected the mistake on the original post and I ask readers to take note of the change.
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
More Resources
|
About Wyeth
- Answers.com
